CA-VELODYNE-LIDAR,-INC.
16.6.2020 14:02:13 CEST | Business Wire | Press release
Velodyne Lidar, Inc. today announced a multi-year partnership agreement with Outsight, the company that is a leading innovator in Smart Cities monitoring. Outsight uses Velodyne Lidar sensing technology in its 3D Semantic Camera system that helps businesses and governments improve the analysis and management of people flow and assets in large crowded environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200616005074/en/
Velodyne’s lidar sensors enable the 3D Semantic Camera solution to capture 3D data and track people and objects in a way that preserves anonymity and trust. The autonomous system merges lidar data capture with RGB color data with an embedded AI processing unit to create a premises-wide, detailed situational understanding of facilities, such as airports, shopping malls and train stations.
In a Smart City application, 3D Semantic Cameras provide operators of public spaces access to real-time data and analysis without compromising private data protection. The solution is being deployed at Paris-Charles de Gaulle airport to optimize the passenger journey, improve queue and asset management, and enhance compliance and safety.
Outsight’s 3D Semantic Cameras can also be deployed to support social distancing and public health. The solution can track individuals based on selected criteria, such as lack of physical distancing, high temperature or not wearing a mask, without having to visually identify them. The Outsight device then can alert the operator when an abnormal event is detected, saving time and resources while optimizing crowd flows.
“Velodyne’s lidar sensors play an essential role in helping our platform capture, process and understand congested environments so operators can work to increase operational efficiency and security,” said Cedric Hutchings, CEO, Outsight. “The Velodyne lidar sensors allow us to track each individual person and object with centimeter-level precision. They enable our solutions to precisely monitor movements, velocity and interactions between all persons and objects in real time.”
“Outsight uses Velodyne’s lidar technology to bring a totally new approach to real-time situational awareness on what’s happening in busy spaces, such as airports,” said Jon Barad, Vice President of Business Development, Velodyne Lidar. “Their system helps organizations move away from traditional surveillance to create a more intelligent infrastructure that tracks people and objects in a more reliable way.”
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.
About Outsight
Outsight develops a 3D Semantic Camera, a revolutionary kind of sensor that brings Full Situation Awareness to Smart Machines and Monitoring Solutions. This sensor combines software and hardware to create sensor innovations such as remote material identification with comprehensive real-time 3D data processing. This technology provides an unprecedented and cost-efficient ability for systems to perceive, understand and ultimately interact with their surroundings in real time. Outsight believes in making a smarter and safer world by empowering cars, drones, robots and monitoring solutions with the superhuman capabilities provided by their 3D Semantic Camera. Their international team of scientists and engineers operates out of Paris, Helsinki and San Francisco.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005074/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom